The company is poised to grow, even if it must shut down its compounded GLP-1 agonist business. The stock's valuation is jaw-droppingly cheap for what the business is already doing without GLP-1 ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

The GLP-1 agonists won’t be cheap any time soon as generic versions remain far in the future: The US patents for Ozempic and Wegovy won’t expire for another six or seven years. It is true that ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they really work? Zoë Beaty looks at how the health landscape is rapidly changing to ...

Average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 -- the lowest average recorded in a ...

Their VK2735 drug is a GLP-1 dual agonist being developed for patients ... check out our report about the cheapest AI stock. Disclosure: None. Insider Monkey focuses on uncovering the best ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Their VK2735 drug is a GLP-1 dual agonist being developed for patients ... check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stock To Buy Now and 30 Most Important AI ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...